Released May 6, 2024, before the open
10-Q filed May 6, 2024, 36 days after period end · 0001628280-24-020455
Q1 2024 · 10-Q
Revenue$5.05M$5.05M −4.9% vs Q1 2023−12.5% vs Q4 2023
Net Income-$25.02M-$25.02M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.59-$0.59 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$28,194,000N/M
Operating Cash Flow-$29,345,000N/M
Free Cash Flowderived-$29,446,000N/M
Margins · derived
Operating margin-558.3%+69.3 pt vs Q1 2023
Net margin-495.4%+78.9 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $5.05M | $5.31M | $3.92M | $286.00K |
| Net Income | -$25.02M | -$30.49M | -$26.91M | -$22.99M |
| EPS Diluted | -$0.59 | -$0.73 | -$0.65 | -$0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR